High Pretreatment Level of Neutrophil to Lymphocyte Ratio, Monocyte to Lymphocyte Ratio and Other Factors Associated with Delayed Sputum Conversion in Patients with Pulmonary Tuberculosis

Figures & data

Figure 1 Flow diagram of study cases and controls included in data analysis.

Table 1 The Characteristics of Subjects According to Case and Control Groups

Variable	Case	Control
Age (years, mean ±SD)	40.55 ±16.06 (19–75)	40.71 ±15.26 (18–76)
Gender (n, %)
Male	19 (61.3%)	19 (61.3%)
Female	12 (38.7%)	12 (38.7%)
BMI (kg/m^2, mean ±SD)	18.18 ±2.92 (13.1–23.7)	19.24 ±4.89 (18.3–27.67)
Diabetes (n, %)
Yes	8 (25.8%)	4 (12.9%)
No	23 (74.2%)	27 (87.1%)
HIV (n, %)
Yes	5 (16.1%)	7 (22.6%)
No	26 (83.9%)	24 (77.4%)
Smoking (n, %)
Yes	5 (16.1%)	4 (12.9%)
No	26 (83.9%)	27 (87.1%)
NLR (mean ±SD)	8.74 ±3.87 (1.47–17.4)	6.24 ±4.50 (1.3–23.3)
MLR (mean ±SD)	0.97 ±0.77 (0.28–4.70)	0.45 ±0.19 (0.13–0.90)

Abbreviations: BMI, body mass index; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio.

Figure 2 Receiver operating characteristics (ROC) curve of high pre-treatment NLR and MLR as risk factors of delayed intensive phase sputum conversion.

Table 2 Bivariate Analysis of NLR, MLR, and Other Variables as Risk Factors for Delayed Intensive Phase Sputum Conversion

Variable	Case	Control	OR	95% CI	P value
NLR
≥5.065	26 (83.9%)	12 (38.7%)	8.23	2.48–27.32	<0.001*
<5.065	5 (16.1%)	19 (61.3%)
MLR
≥0.585	25 (80.6%)	9 (29.0%)	10.18	3.13–33.18	<0.001*
<0.585	6 (19.4%)	22 (71.0%)
BMI
<18.5	18 (58.1%)	10 (32.3%)	2.91	1.03–8.20	0.041*
≥18.5	13 (41.9%)	21 (67.7%)
Smoking
Yes	5 (16.1%)	4 (12.9%)	1.30	0.31–5.37	0.718
No	26 (83.9%)	27 (87.1%)
Diabetes
Yes	8 (25.8%)	4 (12.9%)	2.35	0.62–8.81	0.190
No	23 (74.2%)	27 (87.1%)
HIV
Yes	5 (16.1%)	7 (22.6%)	0.66	0.18–2.36	0.520
No	26 (83.9%)	24 (77.4%)

Note: *Significant at p< 0.05.

Abbreviations: BMI, body mass index; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio.

Table 3 Multivariate Analysis of High Pre-treatment NLR and MLR as Risk Factors for Delayed Intensive Phase Sputum Conversion

Variable	AOR	95% CI	P value
NLR ≥5.065	3.370	0.714–15.910	0.125
MLR ≥0.585	30.802	3.229–287.558	0.003*
BMI<18.5	10.942	1.121–98.563	0.033*
Smoking	0.977	0.124–7.705	0.982
DM	1.093	0.130–9.180	0.935
HIV	0.500	0.091–2.738	0.424

Note: *Significant at p< 0.05.

Abbreviations: BMI, body mass index; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; DM, diabetes mellitus; AOR, adjusted odds ratio.